INTRODUCTION: Type 2 diabetes mellitus (DM) is associated with hyperinsulinemia, which may lead to increased risk of carcinogenesis by increasing insulin-like growth factor-1 level. In this study, we sought to determine the association between type 2 DM and colon adenomas. METHODS: In this retrospective case-control study, all the colonoscopies performed in an urban medical center during a 3-year period were reviewed. Patients with adenomatous polyps were considered as cases (n = 261). Age- and sex-matched controls with a 2:1 ratio were selected (n = 522). Among diabetic subjects, the association of different anti-diabetic medications and HbA1C level with high-risk adenoma features was analyzed. RESULTS: Type 2 DM was significantly associated with colon adenomas (odds ratio (OR) = 1.45, 95% confidence interval (CI) = 1.05-2.01, p = 0.024). Exposure to insulin (OR = 1.734, 95% CI = 1.13-2.65, p = 0.013) and thiazolidinediones (OR = 2.83, 95% CI = 1.28-6.26, p = 0.01) was associated with developing adenomas. Neither the type of antidiabetic medication nor the level of HbA1C was a predictor for high-risk adenomas. Smoking (OR = 1.47, 95% CI = 1.07-2.02, p = 0.02), use of aspirin (OR = 1.59, 95% CI = 1.15-2.20, p = 0.005), and statins (OR = 1.54, 95% CI = 1.13-2.10, p = 0.007) appeared to increase the risk of adenomas. CONCLUSION: This study shows a significant association between type 2 DM and colon adenomas. Establishing this association may lead to inclusion of diabetic patients in the high-risk group for developing colorectal cancer.
INTRODUCTION:Type 2 diabetes mellitus (DM) is associated with hyperinsulinemia, which may lead to increased risk of carcinogenesis by increasing insulin-like growth factor-1 level. In this study, we sought to determine the association between type 2 DM and colon adenomas. METHODS: In this retrospective case-control study, all the colonoscopies performed in an urban medical center during a 3-year period were reviewed. Patients with adenomatous polyps were considered as cases (n = 261). Age- and sex-matched controls with a 2:1 ratio were selected (n = 522). Among diabetic subjects, the association of different anti-diabetic medications and HbA1C level with high-risk adenoma features was analyzed. RESULTS: Type 2 DM was significantly associated with colon adenomas (odds ratio (OR) = 1.45, 95% confidence interval (CI) = 1.05-2.01, p = 0.024). Exposure to insulin (OR = 1.734, 95% CI = 1.13-2.65, p = 0.013) and thiazolidinediones (OR = 2.83, 95% CI = 1.28-6.26, p = 0.01) was associated with developing adenomas. Neither the type of antidiabetic medication nor the level of HbA1C was a predictor for high-risk adenomas. Smoking (OR = 1.47, 95% CI = 1.07-2.02, p = 0.02), use of aspirin (OR = 1.59, 95% CI = 1.15-2.20, p = 0.005), and statins (OR = 1.54, 95% CI = 1.13-2.10, p = 0.007) appeared to increase the risk of adenomas. CONCLUSION: This study shows a significant association between type 2 DM and colon adenomas. Establishing this association may lead to inclusion of diabeticpatients in the high-risk group for developing colorectal cancer.
Authors: J Ma; M N Pollak; E Giovannucci; J M Chan; Y Tao; C H Hennekens; M J Stampfer Journal: J Natl Cancer Inst Date: 1999-04-07 Impact factor: 13.506
Authors: Alaa Rostom; Catherine Dubé; Gabriela Lewin; Alexander Tsertsvadze; Nicholas Barrowman; Catherine Code; Margaret Sampson; David Moher Journal: Ann Intern Med Date: 2007-03-06 Impact factor: 25.391
Authors: S Kono; S Honjo; I Todoroki; M Nishiwaki; H Hamada; H Nishikawa; H Koga; S Ogawa; K Nakagawa Journal: Cancer Causes Control Date: 1998-08 Impact factor: 2.506
Authors: Rangaswamy Govindarajan; Luke Ratnasinghe; Debra L Simmons; Eric R Siegel; Madhu V Midathada; Lawrence Kim; Peter J Kim; Randall J Owens; Nicholas P Lang Journal: J Clin Oncol Date: 2007-04-20 Impact factor: 44.544
Authors: S J Winawer; A G Zauber; M N Ho; M J O'Brien; L S Gottlieb; S S Sternberg; J D Waye; M Schapiro; J H Bond; J F Panish Journal: N Engl J Med Date: 1993-12-30 Impact factor: 91.245
Authors: Paul C Schroy; Alison M Coe; Shamini R Mylvaganam; Lynne B Ahn; Maria A Lydotes; Patricia A Robinson; Julie T Davis; Clara A Chen; Jacqueline Ashba; Michael L Atkinson; Graham A Colditz; Timothy C Heeren Journal: Cancer Prev Res (Phila) Date: 2012-06-11
Authors: Hongha T Vu; Nneka Ufere; Yan Yan; Jean S Wang; Dayna S Early; Jill E Elwing Journal: World J Gastroenterol Date: 2014-06-14 Impact factor: 5.742
Authors: Celina N Santiago; Samara Rifkin; Julia Drewes; Gerard Mullin; Emma Spence; Linda M Hylind; Joell J Gills; David Kafonek; David M Cromwell; Louis La Luna; Francis Giardello; Cynthia L Sears Journal: Cancer Prev Res (Phila) Date: 2021-05-04
Authors: Aimee S James; Phillip Chisholm; Kathleen Y Wolin; Melanie Baxter; Kimberly Kaphingst; Nicholas O Davidson Journal: J Cancer Epidemiol Date: 2012-07-29